# Skyrizi

NDC: 0074-4059
Generic name: risankizumab-rzaa
Labeler / Manufacturer: AbbVie Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20260612

FDA application: BLA761105

## Active ingredients

- RISANKIZUMAB: 55 mg/.37mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0074-4059"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0074-4059
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7148c8eb-b39e-e20a-6494-a6df82392858